Search

Your search keyword '"Bannert, B"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Bannert, B" Remove constraint Author: "Bannert, B"
108 results on '"Bannert, B"'

Search Results

1. POS1320 FUNCTIONAL MAPPING OF AUTOIMMUNE PATIENTS BASED ON SERUM IMMUNE COMPLEXES REVEALS A COMMON TLR7/8 ENDOTYPE

2. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2)

4. Brauchen wir noch klinische Studien in der Rheumatologie?

5. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

6. POS0107 ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

7. POS0512 ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING

9. Impact du statut sérologique du facteur rhumatoïde (FR) et des anticorps anti-protéines citrullinées (ACPA) sur le maintien thérapeutique de l’abatacept (ABA) à 2 ans chez des patients (pts) atteints de polyarthrite rhumatoïde (PR)

11. POS0447 PHYSICAL FUNCTION IN PATIENTS WITH RA, STRATIFIED BY SEROSTATUS AND TREATMENT LINE, FOLLOWING SC ABATACEPT: POST HOC ANALYSIS OF AN OBSERVATIONAL, 2-YEAR STUDY CONDUCTED IN ROUTINE CLINICAL PRACTICE (ASCORE)

12. POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY

13. AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING

14. OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA

15. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

18. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis

20. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen

21. In vitro und in vivo Effekte einer Therapie mit Tofacitinib auf humane B-Zellen

22. Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA) by functional MRI of the Brain – an Interim Analysis of an ongoing Investigator initiated Phase III Trial

23. DEKAVIL (F8IL10): A novel therapeutic approach for the treatment of rheumatoid arthritis

24. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

26. THU0040 Enhancement of early human b cell development by jak inhibition

27. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen

28. THU0105 Prediction of response to CERTOLIZUMAB-PEGOL in rheumatoid arthritis (PRECEPRA) by functional MRI of the brain – an interim analysis of an ongoing investigator initiated phase III trial

29. Do we still need clinical studies in rheumatology?

30. Studienergebnisse der Inter-SpA: Sensitivität und Spezifität von IgA-anti-CD74 bei früher axialer Spondyloarthritis (axSpA)

31. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

32. THU0414 Inter SPA: Sensitivity and Specifity of Autoantibodies against CD74 in Early Axial Spondyloarthritis

35. Brauchen wir noch klinische Studien in der Rheumatologie?

39. Causes and risk factors for death in systemic sclerosis – A study from the EULAR Scleroderma Trials And Research (EUSTAR) data base

43. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

49. Sarcocystis simonyi sp. nov. (Apicomplexa: Sarcocystidae) from the endangered Hierro giant lizard Gallotia simonyi (Reptilia: Lacertidae).

Catalog

Books, media, physical & digital resources